Nxera Pharma (4565) Corporate presentation summary

Strategic direction and business model

• Focuses on global innovation with local specialization, leveraging a Nobel Prize-winning founder and proprietary drug discovery platforms, including StaR™ and NxWave™.

• Operates with agile, bilingual teams and novel go-to-market strategies, aiming to address major healthcare challenges worldwide.

• Grows through strategic acquisitions, including Arakis, Heptares, and Idorsia Japan/Korea, and rebranded as Nxera Pharma.

Pipeline and R&D highlights

• Maintains a robust pipeline with in-house and partnered programs targeting obesity, metabolic diseases, schizophrenia, IBD, solid tumors, and rare diseases.

• Key assets include NXE'744 (EP4 agonist for IBD), NXE'149 (GPR52 agonist for schizophrenia), and NXE'732 (EP4 antagonist for solid tumors), all advancing through clinical phases.

• Collaborates with major pharma partners (Lilly, AbbVie, Neurocrine, Centessa, Pfizer) on multiple discovery and clinical programs.

Commercial performance and financials

• Commercial business saw 39% YoY revenue growth in 2025, driven by Pivlaz (+7%) and Quviviq (+224%).

• Despite commercial growth, lower milestone receipts led to a core operating loss in 2025; platform business increased R&D spend.

• 2026 guidance targets JPY 19.5bn+ net product sales, cost reductions over 10%, and full-year IFRS profitability.